Valuation: Arctic Bioscience

Market Cap 80.87M 8.57M 7.4M 6.95M 6.32M 11.89M 819M 12.08M 81.47M 31.85M 410M 32.16M 31.47M 1.36B P/E 2026 *
-3.37x
P/E 2027 * -
Enterprise Value 147M 15.56M 13.44M 12.63M 11.48M 21.59M 1.49B 21.95M 148M 57.85M 745M 58.41M 57.15M 2.48B EV / Sales 2026 *
2.53x
EV / Sales 2027 * -
Free-Float
47.75%
Yield 2026 *
-
Yield 2027 * -
1 week-4.76%
Current month+12.36%
1 month-7.41%
3 months-1.32%
6 months-10.18%
Current year-8.54%
1 week 2.72
Extreme 2.72
3.29
1 month 2.51
Extreme 2.51
3.29
Current year 2.51
Extreme 2.51
3.67
1 year 2.51
Extreme 2.51
4.65
3 years 1.65
Extreme 1.65
16.8
5 years 1.65
Extreme 1.65
21.7
10 years 1.65
Extreme 1.65
32
Manager TitleAgeSince
Chief Executive Officer 60 2010-12-31
Chief Executive Officer 54 2022-02-28
Director of Finance/CFO 47 2022-03-31
Director TitleAgeSince
Chairman 68 2015-11-30
Director/Board Member 55 2014-12-31
Director/Board Member 46 2020-12-31
Date Insider Type Main position Quantity % Market Cap.
4/24/23 Buy

Director

943,833 3.8641%
4/24/23 Buy

Director

943,833 3.8641%
2/23/23 Buy

Chief Technology Officer

11,500 0.0472%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-4.76%-14.29%-69.94% 8.51M
-2.27%-0.52%+72.34%+119.25% 1,078B
-0.57%+0.73%+49.46%+50.56% 632B
-0.33%+1.63%+22.17%+64.22% 443B
-1.99%-3.32%+41.98%+34.08% 356B
-1.05%-2.81%+24.22%+34.67% 289B
-2.12%-3.67%-1.09%+3.11% 245B
-0.80%+0.85%+42.76%+58.80% 226B
-1.19%-3.41%-9.18%-52.41% 204B
-0.03%+3.62%+15.97%+72.86% 171B
Average -1.04%+1.09%+24.43%+31.52% 364.37B
Weighted average by Cap. -1.37%+1.30%+41.51%+62.28%

Financials

2026 *2027 *
Net sales 58M 6.14M 5.31M 4.99M 4.54M 8.53M 588M 8.67M 58.43M 22.85M 294M 23.07M 22.57M 978M -
Net income -24M -2.54M -2.2M -2.06M -1.88M -3.53M -243M -3.59M -24.18M -9.45M -122M -9.55M -9.34M -405M -
Net Debt 66M 6.99M 6.04M 5.67M 5.16M 9.7M 669M 9.86M 66.49M 26M 335M 26.25M 25.68M 1.11B -
Logo Arctic Bioscience
Arctic Bioscience AS is a Norway-based biotech company developing and commercializing both pharmaceutical and nutraceutical products based on the properties of herring roe oil. Arctic Bioscience’s purpose is to provide people with autoimmune disorders an effective and healthy therapy based on marine membrane lipids. The Company is developing HRO350 - a novel investigational drug candidate. HRO350 is being developed for treatment of patients with mild-to-moderate psoriasis. The Company's product portfolio includes, among others, Romega, which is a producer of an omega-3 dietary supplement made from herring roe in a form of a capsule, as well as herring caviar oil and herring caviar protein offered to Business-to-Business (B2B) customers. Arctic Bioscience AS has three subsidiaries Arctic Nutrition AS, Romega AS and Arctic Biopharma AS.
Employees
19
Date Price Change Volume
26-08-14 NOK 3.000 0.00% 1,783
26-08-13 NOK 3.000 -1.64% 16,957
26-08-12 NOK 3.050 +1.67% 11,134
26-08-11 NOK 3.000 -1.96% 22,780
26-08-10 NOK 3.060 -2.86% 6,869
Trader
-
Investor
-
Global
-
Quality
ESG MSCI
-

Annual profits - Rate of surprise